CARTITUDE-4: Deeper response to bridging therapy with cilta-cel is associated with improved survival outcomes across cytogenetic risk subgroups

ASH 2025

Multiple Myeloma (MM)

CARTITUDE-4: Cilta-cel achieves sustained PFS and durable remissions in standard-risk RRMM

Multiple Myeloma (MM)

Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial

Lancet Oncol

Einsele H, San-Miguel J, Dhakal B, Touzeau C, Leleu X, van de Donk NW, Sidana S, Oriol A, Cohen YC, Harrison SJ, Mateos MV, Martínez-López J, Corradini P, Karlin L, Chen D, Li Q, Yeh TM, Li K, Plaks V, Slaughter A, Lonardi C, Benachour N, Ghosh A, Vogel M, Schecter JM, Lendvai N, Koneru M, Patel N, Florendo E, Ho PJ, Popat R

doi: 10.1016/S1470-2045(25)00653-9

Multiple Myeloma (MM)

Survival Outcomes with Cilta-cel Versus Conventional Treatment Regimens for Patients with Lenalidomide-Refractory Multiple Myeloma Using Inverse Probability of Treatment Weighting

Adv Ther

Fonseca R, Diels J, Ghilotti F, Mendes J, Van Hoorenbeeck S, Lee S, Schecter JM, Lendvai N, Patel N, Triguero A, Alsdorf W, van de Donk NWCJ, Ursi M

doi: 10.1007/s12325-025-03278-5

ASH 2025

Lymphoma

Real-world comparison of commercial CAR T-cell therapies demonstrates comparable outcomes between axi-cel and liso-cel in R/R LBCL

EHA 2026

Multiple Myeloma (MM)

MajesTEC-3: Teclistamab plus daratumumab maintain improved PFS and MRD negativity across high-risk multiple myeloma populations

Leukemia

Impact of Cytogenetic Response to Therapy on Long-Term Survival in Acute Myeloid Leukemia

Am J Hematol

Hanna J, Zabor EC, Albliwi M, El-Asmar J, Nurse DP, Bawwab A, Abuamsha H, Abu-Farsakh Y, Batah H, Rauf A, Nakitandwe J, Bosler DS, Jain AG, Molina JC, Balderman S, Singh A, Gerds AT, Mukherjee S, Sobecks RM, Advani AS, Carraway HE, Astbury C, Mustafa Ali MK

doi: 10.1002/ajh.70000

Lung, Respiratory and Thoracic Cancer

Risk Factors Associated with Suboptimal Real-World Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Treated with Front-Line Recommended Therapy

Adv Ther

Spira AI, Ran T, Lin I, Chen C, He A, Belani N, Du S

doi: 10.1007/s12325-025-03234-3

EHA/ICML 2025

Lymphoma

Expanding the Curative Potential of CAR T-Cell Therapy

Multiple Myeloma (MM)

Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma

Blood Cancer J

Hashmi H, Sebastian T, Rajeeve S, Farzana T, Firestone RS, Jurgens EM, Miller KC, Maura F, Lesokhin AM, Tan CR, Shah GL, Korde N, Landau HJ, Merz M, Scordo M, Hassoun H, Maclachlan KH, Shah UA, Hultcrantz ML, Derkach A, Nemirovsky D, Giralt S, Mailankody S, Usmani SZ

doi: 10.1038/s41408-026-01494-y

Related content

CARTITUDE-4: Cilta-cel achieves sustained PFS and durable remissions in standard-risk RRMM

Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial

Survival Outcomes with Cilta-cel Versus Conventional Treatment Regimens for Patients with Lenalidomide-Refractory Multiple Myeloma Using Inverse Probability of Treatment Weighting

Real-world comparison of commercial CAR T-cell therapies demonstrates comparable outcomes between axi-cel and liso-cel in R/R LBCL

MajesTEC-3: Teclistamab plus daratumumab maintain improved PFS and MRD negativity across high-risk multiple myeloma populations

Impact of Cytogenetic Response to Therapy on Long-Term Survival in Acute Myeloid Leukemia

Risk Factors Associated with Suboptimal Real-World Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Treated with Front-Line Recommended Therapy

Expanding the Curative Potential of CAR T-Cell Therapy

Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma